This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology

Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology

Format

Roundtable

Time to Complete

1 hour

Released

August 28, 2018

Expires

August 28, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Sponsored by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by an educational grant from Amgen, Inc.

Program Description

Treatment decisions for hyperlipidemia are increasingly challenging due to changing guidelines and a new class of therapies, the PCSK9 inhibitors. Further, clinicians must have competence in identifying high-risk patients who may require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of eligible at-risk patients. Interventional cardiologists require up-to-date knowledge of these new therapies and data since they are likely to encounter high-risk patients with hyperlipidemia.

Intended Audience

This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, and nurses involved in the management and treatment of patients with hyperlipidemia.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
  • Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
  • Identify high-risk patients who may be candidates for a PCSK9 inhibitor
  • Formulate individualized treatment strategies for complex patients based on available evidence
  • Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

Faculty

Rajesh Dave, MD, FACC, FSCAI (Moderator)
Chief Medical Executive
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, PA

Dr. Dave discloses the following:
Board Member/Advisory Panel/Speakers Bureau: Abbott Vascular, Amgen, Aralez, Astellas, Boston Scientific Corporation, Bristol-Myers Squibb, Chiesi USA Inc, Pfizer, QT Vascular, Regeneron, and Sanofi-Aventis
Sources of Funding for Research: Abbott Vascular

Nihar Desai, MD, MPH
Assistant Professor of Medicine
Yale School of Medicine
New Haven, CT

Dr. Desai discloses the following:
Honoraria: Amgen, Boehringer Ingelheim, Cytokinetics, and Relypsa
Research Support: Amgen, Boehringer Ingelheim, and Relypsa

Robert Giugliano, MD, SM
Associate Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Dr. Giugliano discloses the following:
Consultant: Amarin, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, CVS Caremark, Daiichi Sankyo, GlaxoSmithKline, Lexicon, Merck, Portola, and Pfizer
Honoraria: Amgen, Daiichi Sankyo, and Merck
Research Support: Amgen

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and the Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Inclisiran

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

To obtain credit, a score of 60% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Katlyn Cooper
kcooper@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue